PFS
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Eriko Tokunaga, Hiroji Iwata, Mitsuya Itoh, Tetsuhiko Taira, Tatsuya Toyama, Toshiro Mizuno, Akihiko Osaki, Yasuhiro Yanagita, Seigo Nakamura, Rikiya Nakamura, Tomoko Sambe, Toshiaki Ozaki, Gaia Schiavon, Sacha J Howell, Masakazu Toi
Breast Cancer 32(1) 132-143
BACKGROUND: In CAPItello-291, capivasertib-fulvestrant significantly improved progression-free survival (PFS) versus placebo-fulvestrant in the overall and PIK3CA/AKT1/PTEN-altered population with hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer. Capivasertib-fulvestrant is approved in Japan for the treatment of patients with one or more tumor biomarker alterations (PIK3CA, AKT1 or PTEN). Here, we report outcomes in the CAPItello-291 subgroup of patients from Japan. METHODS: Adults with HR-positive/HER2-negative advanced breast cancer whose disease had relapsed or progressed during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy, were randomly assigned (1:1 ratio) to receive capivasertib or placebo, plus fulvestrant. The dual primary endpoint was investigator-assessed PFS in the overall and PIK3CA/AKT1/PTEN-altered population. Safety was a secondary endpoint. RESULTS: Of 708 patients randomized in CAPItello-291, 78 were from Japan (37 randomized to capivasertib-fulvestrant and 41 to placebo-fulvestrant). In the Japan subgroup, PFS numerically favored the capivasertib-fulvestrant arm (hazard ratio 0.73; 95% CI 0.40-1.28), consistent with the analysis of PFS in the global population. Similarly, in the Japan subgroup of patients with PIK3CA/AKT1/PTEN-altered tumors, PFS favored the capivasertib-fulvestrant arm (hazard ratio 0.65; 95% CI 0.29-1.39), consistent with the global population. The adverse event profile of capivasertib-fulvestrant in the Japan subgroup was broadly similar to that in the global population; no new safety concerns were identified. CONCLUSION: Outcomes in the Japan subgroup were broadly similar to those of the global population, supporting the clinical benefit of capivasertib-fulvestrant in treating HR-positive/HER2-negative advanced breast cancer that has progressed on, or after, an endocrine-based regimen.
2 个 Figure · 4 个 KM 面板
Fig. 1 Investigator-assessed PFS in a the Japan subgroup, and b the global CAPItello-291 population. The hazard ratio was estimated in the Japan subgroup using the Cox proportional hazards model stratified by previous CDK4/6 inhibitor use, and in the global CAPItello-291 population using the Cox proportional hazards model stratified according to the presence or absence of liver metastases, previous CDK4/6 inhibitor use, and geographic region. Tick marks indicate censored data. b From New England Journal of Medicine . Turner et al. [16]. Copyright © (2023) Massachusetts Medical Society. Reprinted with permission. CI confidence interval, PFS progression-free survival
Fig. 2 Investigator-assessed PFS in patients with PIK3CA/AKT1/PTEN -altered tumors in a the Japan subgroup, and b the global CAPItello-291 population. The hazard ratio was estimated in the Japan subgroup using an unstratified Cox proportional hazards model, and in the global CAPItello-291 population using the Cox proportional hazards model stratified according to the presence or absence of liver metastases and previous CDK4/6 inhibitor use. Tick marks indicate censored data. b New England Journal of Medicine . Turner et al. [16]. Copyright © (2023) Massachusetts Medical Society. Reprinted with permission. AKT1 Akt serine/threonine kinase 1, CI confidence interval, NC not calculable, PFS progression-free survival, PIK3CA catalytic subunit of phosphatidylinositol-3-kinase, PTEN phosphatase and tensin homolog
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。